Molecular (functional) imaging for radiotherapy applications: An RTOG symposium

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 2, 2003, Pages 294-301

  Chapman, J D ^a   Bradley, Jeffrey D ^b   Eary, Janet F ^c   Haubner, Roland ^d   Larson, S M ^e   Michalski, Jeff Michael ^b   Okunieff, Paul G ^f   Strauss, H W ^e   Ung, Y C ^g   Welch, Michael J ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; BMS 194796; FLUORODEOXYGLUCOSE; MISONIDAZOLE; NUCLEOSIDE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RADIOISOTOPE; THYMIDINE; TRACER;

CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEVICE; HUMAN; HYPOXIA; IMAGING SYSTEM; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOSENSITIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TUMOR BIOPSY;

ANIMALS; CELL HYPOXIA; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RECEPTORS, CELL SURFACE; RESEARCH; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037297657     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04215-3     Document Type: Conference Paper

References (45)

1. 2. Am J Physiol. 145:1945;253-263.
2. st UNESCO International Conference of Radioisotopes in Sci Res, Paris, 1957. 1958;Pergamon Press, New York.
3. Ter-Pogossian M.M., Phelps M.E., Hoffman E.J., et al. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology. 114:1975;89-98.
4. 77Br]bromoestradiol Dosimetry and preliminary clinical studies . J Nucl Med. 23:1982;425-430.
5. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer PET imaging of estrogen receptors . Radiology. 169:1988;45-48.
6. Welch M.J., Downer J.B., Katzenellenbogen J.A. Steroid hormone receptors as targets for diagnostic imaging. Mather S.J. Current directions in radiopharmaceutical research and development. 1996;137-156 Kluwer Academic Publishers, New York.
7. Coleman R.E. FDG imaging. Nucl Med Biol. 27:2000;689-690.
8. Shreve P.D., Anzai Y., Wahl R.L. Pitfalls in oncological diagnosis with FDG PET imaging Physiologic and benign variants . Radiographics. 19:1999;61-77.
9. 18FDG Hybrid PET and CT fusion improves target volume definition in treatment planning for carcinomas of the anal canal. Int J Radiat Oncol Biol Phys. 50:2001;1416.
10. Scherrer A., Reboul F., Martin D., et al. CT of malignant anal canal tumors. Radiographics. 10:1990;433-453.
11. Davey P., Saibel E.A., Wong R. Bipedal lymphography in the management of carcinoma of the anal canal. Br J Radiol. 69:1996;632-635.
12. 18FDT-PET/CT integration Impact on target and critical organs in radiation therapy of non-small cell lung carcinoma, a prospective study . Int J Radiat Oncol Biol Phys. 52:2002;339-350.
13. 18FDG-hybrid PET fusion . Int J Radiat Oncol Biol Phys. 51:2001;923-931.
14. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 343:2000;254-261.
15. MacManus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma Powerful correlation with survival and high impact on treatment . Cancer. 92:2001;886-895.
16. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 6:1994;509-518.
17. Chapman J.D., Baer K., Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 43:1983;1523-1528.
18. Chapman J.D., Engelhardt E.L., Stobbe C.C., et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 46:1998;229-237.
19. Chapman J.D., Schneider R.F., Urbain J.-L., et al. SPECT/PET assays for tissue oxygenation. Semin Radiat Oncol. 11:2001;47-57.
20. Englehardt E.L., Schneider R.F., Seeholzer S.H., et al. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. J Nucl Med. 43:2002;837-850.
21. 99mTc-BnAO (HL-91) A non-nitroaromatic compound for hypoxic cell detection . Int J Radiat Oncol Biol Phys. 42:1998;737-740.
22. Chapman J.D., Urtasun R.C. Tumor hypoxia and radioresistance From laboratory to the clinic . Movsas B., Langer C., Goldberg L. Controversies and issues in lung cancer. 2001;481-497 Marcel Dekker, Inc, New York.
23. Howe F.A., Robinson S.P., McIntyre D.J., et al. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed. 14:2001;497-506.
24. Zhao D., Constantinescu A., Hahn E.W., et al. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int J Radiat Oncol Biol Phys. 53:2002;744-756.
25. Fu K.K., Hammond E., Pajak T.F., et al. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head and neck cancers Results of RTOG 91-08 . Int J Radiat Oncol Biol Phys. 29:1994;661-671.
26. Tjuvajev J.G., Stockhammer G., Desai R., et al. Imaging the expression of transfected genes in vivo. Cancer Res. 55:1995;6126-6132.
27. Dupertuis Y.M., Vazquez M., Mach J.P., et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res. 61:2001;7971-7977.
28. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines . Nucl Med Biol. 29:2002;281-287.
29. Blankenberg F.G., Eckelman W.C., Strauss H.W., et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol. 7:2000;851-867.
30. Weber W.A., Haubner R., Vabuliene E., et al. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med. 45:2001;179-182.
31. Tarli L., Balza E., Viti F., et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 94:1999;192-198.
32. Kuhnast B., Haubner R., Wester H.-J., et al. In vivo evaluation of a labeled decapeptide to image gelatinase activity. J Nucl Med. 43:(Suppl.):2002;370P.
33. Westlin W.F. Integrins as targets for angiogenesis inhibition. Cancer J. 7:(Suppl. 3):2001;139-143.
34. Haubner R., Wester H.J., Reuning U., et al. Radiolabeled α(σ)β3 integrin antagonists A new class of tracers for tumor targeting . J Nucl Med. 40:1999;1061-1071.
35. Haubner R., Wester H.J., Burkhart F., et al. Glycosylated RGD-containing peptides Tracer for tumor targeting and angiogenesis imaging with improved biokinetics . J Nucl Med. 42:2001;326-336.
36. Haubner R., Wester H.J., Weber W.A., et al. Noninvasive imaging of α(σ)β3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
37. Bergers G., Javaherian K., Lo K.M., et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812.
38. Bock M., Bruchertseifer F., Haubner R., et al. Tc-99m-, Re-188- and Y-90-labeled aVb3 antagonists Promising tracer for tumor-induced angiogenesis . J Nucl Med. 41:(Suppl.):2000;41P.
39. van Hagen P.M., Breeman W.A., Bernard H.F., et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 90:2000;186-198.
40. Liu S., Edwards D.S., Ziegler M.C., et al. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 12:2001;624-629.
41. Blankenberg F.G., Strauss H.W. Noninvasive strategies to image cardiovascular apoptosis. Cardiol Clin. 19:2001;165-172.
42. Narula J., Acio E.R., Narula N., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 7:2001;1347-1352.
43. Blankenberg F.G., Tait J.F., Blankenberg T.A., et al. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V. Eur J Nucl Med. 28:2001;1384-1393.
44. Hofstra L., Liem I.H., Dumont E.A., et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 356:2000;209-212.
45. Green A.M., Steinmetz N.D. Monitoring apoptosis in real time. Cancer J. 8:2002;82-92.